<DOC>
	<DOCNO>NCT02115204</DOCNO>
	<brief_summary>Taxane-based adjuvant chemotherapy standard node-positive ( N+ ) early breast cancer ( BC ) . The magnitude benefit intermediate-risk N+ early BC still unclear . West German Study Group `` Arbeitsgemeinschaft Gyn√§kologische Onkologie '' ( WSG-AGO ) EC-Doc large trial evaluate modern sequential taxane-based chemotherapy subgroup 1-3 involved lymph node ( LN ) .</brief_summary>
	<brief_title>4 x Epirubicin , Cyclophosphamide , Followed 4 x Docetaxel Versus 6 x CMF / 6 x CEF</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Female patient Age 1865 year Eastern Cooperative Oncology Group ( ECOG ) status &lt; 2 Surgery : R0resection &gt; = 10 remove axillary lymph node M0 chest xray , bone scintigraphy liver sonography Polyneuropathy Creatinin ( serum ) &gt; 1,4 mg/dl ; Bilirubin ( serum ) &gt; 2,0 mg/dl Cardia dysfunction , ejection fraction &lt; low normal value institution Hematopoeitic insufficiency : leucocytes &lt; 3,5 G/l , thrombocytes &lt; 100 G/l second malignant neoplasia , except curatively treat basalioma skin Surgery six week ( 42 day ) Concurrent pregnancy ; patient childbearing potential must implement highly effective ( less 1 % failure rate ) nonhormonal contraceptive measure study treatment Breast feeding woman Sequential breast cancer Reasons indicate risk poor compliance Patients able consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>